Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-0245

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-0245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Losartan Potassium 50mg 70518 0245 01)

Losartan Potassium 50 mg film-coated tablets packaging label showing quantity of 90 tablets. The label includes the NDC number 70518-0245-01 and states the medication is RX only. Manufacturer is Aurobindo Pharma Ltd., India, with repackaging by RemedyRepack Inc., Indiana.*

FDA Label Image

Losartan Potassium 50mg 70518 0245 02

Losartan Potassium 50 mg film-coated tablets packaging label showing a quantity of 60 tablets. The label includes the NDC number 70518-0245-02 and states the product is RX only. Manufacturer is Aurobindo Pharma Ltd., India, with repackaging details by RemedyRepack Inc., Indiana, PA. Storage instructions and a QR code are also visible.*

FDA Label Image

Remedy Label

Label for Losartan Potassium 50 mg film-coated tablets, quantity 30, repackaged by RemedyRepack Inc. The label includes the NDC number 70518-0245-00, manufacturing info for Aurobindo Pharma Ltd., and handling/storage instructions. The label features the RemedyRepack logo and a QR code.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over time between Atenolol and Losartan Potassium treatments. The x-axis represents the study months up to 66 months, and the y-axis shows the percentage of patients. Losartan Potassium shows a lower incidence compared to Atenolol, indicating an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing percent of patients with fatal or non-fatal stroke over time between atenolol and losartan potassium groups. The horizontal axis shows study months up to 66, and the vertical axis shows stroke percentage up to 8%. The graph includes an annotation of adjusted risk reduction of 25% with p=0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

This figure presents a forest plot comparing primary composite and stroke (fatal/non-fatal) endpoint event rates between Losartan Potassium and Atenolol across demographic subgroups. It shows the number of patients, event rates, and hazard ratios with 95% confidence intervals for age, gender, race, ISH, diabetes, and history of CVD groups, illustrating relative treatment effects.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The graph shows cumulative incidence with a risk reduction of 16.1% and a p-value of 0.022 indicated. Losartan Potassium data is represented by a solid line, and placebo data by a dashed line.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium shown as a detailed molecular diagram with various atoms and bonds illustrating the compound's chemical makeup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.